Finance

Lists
Why is ARTV up 2,13%?
Dive Deeper
ARTV:NASDAQ
Artiva Biotherapeutics Inc
USD 7,18
+2,13%
(+0,15) 1D
30 Sep., 12:49:44 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARTV...
Open
USD 7,10
High
USD 7,40
Low
USD 6,96
Mkt. cap
351,03 m
Avg. vol.
416,11 k
Volume
117,39 k
52-wk high
USD 14,53
52-wk low
USD 2,71
EPS
-USD 3,31
Shares outstanding
48,89 m
No. of employees
115
Open
USD 7,10
High
USD 7,40
Low
USD 6,96
Mkt. cap
351,03 m
Avg. vol.
416,11 k
Volume
117,39 k
52-wk high
USD 14,53
52-wk low
USD 2,71
EPS
-USD 3,31
Shares outstanding
48,89 m
No. of employees
115
About Artiva Biotherapeutics Inc
CEO-
Employees115
Founded2019
Headquarters-
Sector-
Websiteartivabio.com
Analyst ratings
Based on 3 analysts giving stock ratings to ARTV in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for ARTV in the last 3 months.
Highest
Current USD 7,18
USD 41,00 (+471,03%)
Average
USD 38,00 (+429,25%)
Lowest
USD 35,00 (+387,47%)
Analyst
Recommendation
Action
Price target
Projected
Date
Emily Bodnar
H.C. Wainwright
Buy
Maintained
USD 35,00
+387,5%
09/21/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/07/2026
Gil Blum
Needham
Buy
Maintained
USD 41,00
+471%
08/07/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
USD 40,00
+457,1%
05/25/2026
Unknown Analyst
Jefferies
Buy
Maintained
USD 23,00
+220,3%
05/21/2026
Martin Fan
Wedbush
Buy
Maintained
USD 40,00
+457,1%
05/21/2026
David Nierengarten
Wedbush
Buy
Maintained
USD 40,00
+457,1%
05/21/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
17,63 m
16,99 m
19,31 m
21,92 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,26 m
4,94 m
5,12 m
4,96 m
Operating expense
22,90 m
21,93 m
24,43 m
26,89 m
Total operating expenses
22,90 m
21,93 m
24,43 m
26,89 m
Operating income
-22,90 m
-21,93 m
-24,43 m
-26,89 m
Other non operating income
-3,00 k
-1,88 m
2,00 k
-1,00 k
EBT including unusual items
-21,53 m
-20,77 m
-23,52 m
-25,00 m
EBT excluding unusual items
-21,53 m
-22,65 m
-23,52 m
-25,00 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-21,53 m
-20,77 m
-23,52 m
-25,00 m
Net profit margin
-
-
-
-
Earnings per share
-0,88
-0,84
-0,95
-0,63
Interest and investment income
1,37 m
1,16 m
912,00 k
1,89 m
Interest expense
-
-
-
-
Net interest expenses
1,37 m
1,16 m
912,00 k
1,89 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,24 m
-21,27 m
-23,76 m
-26,20 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme